ARTV · Artiva Biotherapeutics, Inc.

Track ARTV — free

$10.22 -0.20 (-1.92%) At close · Sep 11

Russell 2000 member Rebalance outlook locked

Market Cap

$499.66M

48.89M

Up next

Latest filing: 10-Q

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

−$90.82M

Trailing 12 months

Revenue growth YoY

-100.0%

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-15.4%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$349.39M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+61.7%

Year over year · more shares

Price change (1Y)

+284.2%

Trailing year

Short interest

3.8%

Latest settlement · 6.7 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Strong Sentiment Very Bullish Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 15.8 · calm Equity put/call 0.58

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +35%

above

Price vs 50-day avg −4%

below

RSI (14) 38

neutral

MACD trend Negative

52-week position 71%

mid-range

Momentum

relative strength

Strong

1-month return −10%

trailing

6-month return +92%

trailing

YTD return +138%

this year

Relative strength +74%

vs S&P · 6-mo

Sentiment

smart money

Very Bullish

Trend (MA cross) No cross

50d $11 › 200d $8 — 50d above 200d

Institutional flow Accumulating

+80% holders QoQ · +39 funds added

Insider flow Accumulating

Net +$5.6M over 90 days · 80% sells

Short interest Falling

3.76% of float · ▼ -12.4% MoM · 6.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

72 holders — near 2-yr high, broad support

Squeeze score 58

elevated · 0–100

Fundamentals

Weak

Revenue growth −100%

Y/Y

EPS growth +41%

Y/Y

Free cash flow $-79.3M

Quant / Vol

risk profile

Very High

Volatility 182%

annualized · 1-yr

Max drawdown −49%

past year

ATR 6.1%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+35% Bullish

Price vs 50-day avg

−4% Neutral

RSI (14)

38 Neutral

MACD trend

Negative Bearish

52-week position

71% Neutral

Market signals — smart money & positioning

Bullish · 4 of 6

Trend (MA cross) No cross

50d $11 › 200d $8 — 50d above 200d

Institutional flow Accumulating

+80% holders QoQ · +39 funds added

Insider flow Accumulating

Net +$5.6M over 90 days · 80% sells

Short interest Falling

3.76% of float · ▼ -12.4% MoM · 6.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

72 holders — near 2-yr high, broad support

Price context

position in its 52-week range

Range low $2 Now $10 · 71% Range high $13

vs 200-day avg +35% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ARTV Artiva Biotherapeutics, Inc. this stock	$499.66M	+138.2%	-100.0%	—	3.8%
VRTX Vertex Pharmaceuticals Inc / Ma	$130.64B	+13.7%	+46.2%	30.0	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$80.46B	+1.2%	+20.8%	19.4	2.5%
ARGX Argenx SE	$61.22B	+17.1%	—	—	2.0%
MRNA Moderna, Inc.	$57.48B	+388.2%	+4.3%	—	9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

% held: 82.6%
Net QoQ: +23.5M sh
Top holder: RA CAPITAL MANAGEMENT, L.…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

1.8M

Days to cover: 6.7d
Change: -259.7K sh

View

Short Volume

Short vol %

63%

As of: Sep 11, 2026

Short Total

View

Fails to Deliver

FTD shares

279

Value: $3.2K
As of: Aug 14, 2026

View

Off-Exchange

Off-exchange %

47.4%

Week of: Aug 3, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$5.6M

Buyers / Sellers: 1 / 4

Buyers Sellers

View

Financials

Revenue (FY)

Net income (FY): $-83.9M
EPS diluted: $-3.43

View

Filings

SEC Filings

Latest

8-K

Filed: Sep 11, 2026
This year: 17

View

Proposed Sales

Value

$262.2K

Shares: 23.4K
Filed: Sep 8, 2026

View

Exempt Offerings

Offering

$120.0M

Filed: Apr 5, 2021

View

Earnings & Events

Earnings Calls Upcoming

Next call

Sep 14, 2026

Last call: Jun 30, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
ARTV	-8.1%	-9.6%	+92.1%	-9.6%	+138.2%
SPY	-1.2%	-1.8%	+17.8%	-0.4%	+12.1%
vs SPY	-7.0%	-7.8%	+74.3%	-9.2%	+126.2%

Key facts CIK 1817241 CUSIP 04317A107 13F (30d) 34 filings 34 filers Visit website Investor relations

ARTV · Artiva Biotherapeutics, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance